Genclis
Strasbourg, France· Est. 2011
Genclis has developed a technology platform based on its discovery of Transcription Infidelity (“TI”), causing gaps in mRNA. Proteins translated from these mRNA are designated TI proteins and hold specific immunological properties.
Private Company
Total funding raised: $1.8M
About
Genclis has developed a technology platform based on its discovery of Transcription Infidelity (“TI”), causing gaps in mRNA. Proteins translated from these mRNA are designated TI proteins and hold specific immunological properties.
Diagnostics
Funding History
1Total raised:$1.8M
Seed$1.8MSep 15, 2020